Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer

Technology appraisal guidance
Reference number: TA212
Published: 15 December 2010

Colorectal cancer (metastatic) - bevacizumab: response to consultee, commentator and public comments on the ACD and comments from website consultation

Colorectal cancer (metastatic) - bevacizumab: response to consultee, commentator and public comments on the first ACD and comments from website consultation (Issued November 2009)
Colorectal cancer (metastatic) - bevacizumab: response to consultee, commentator and public comments on the second ACD and comments from website consultation (Issued August 2010)

This page was last updated: 09 November 2010